Clinical usefulness of FDG-PET in the diagnosis of lung cancer

Japanese Journal of Lung Cancer

Volumn 46, Issue 2, 2006, Pages 127-131

  Uramoto, Hidetaka ^a   Sugio, Kenji ^a   Nakata, Shoji ^a   So, Tetsuya ^a   Ono, Kenji ^a   Sugaya, Masakazu ^a   Hanagiri, Takeshi ^a   Honma, Minoru ^b   Yasumoto, Kosei ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b Fukuoka Wajiro PET Diagnostic Imaging Clinic   (Japan)

Author keywords

False negative; False positive; FDG PET; Lung cancer

Indexed keywords

FLUORODEOXYGLUCOSE;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FALSE NEGATIVE RESULT; FEMALE; FIBROSIS; HISTIOCYTOMA; HISTOPATHOLOGY; HUMAN; HYPERPLASIA; INFLAMMATION; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG HILUS; LUNG LOBECTOMY; LUNG NODULE; LUNG RESECTION; LYMPH NODE METASTASIS; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDIASTINUM LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; THORAX TUMOR;

EID: 33745668409     PISSN: 03869628     EISSN: None     Source Type: Journal    
DOI: 10.2482/haigan.46.127     Document Type: Article

References (31)

1. Gould MK, Kuschner WG, Rydzak CE, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med. 2003;139:879-892.
2. Lowe VJ, Fletcher JW, Gobar L, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol. 1998;16:1075-1084.
3. Gould MK, Maclean CC, Kuschner WG, et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA. 2001;285:914-924.
4. Gambhir SS, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med. 2001;42:1s-93s.
5. Kubota K. From tumor biology to clinical Pet a review of positron emission tomography (PET) in oncology. Ann Nucl Med. 2001;15:471-486.
6. Demura Y, Tsuchida T, Ishizaki T, et al. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med. 2003;44:540-548.
7. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002;359:1388-1393.
8. Kelloff GJ, Hoffman JM, Johnson B, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res. 2005;11:2785-2808.
9. Kang WJ, Chung JK, So Y, et al. Differentiation of mediastinal FDG uptake observed in patients with non-thoracic tumours. Eur J Nucl Med Mol Imaging. 2004;31:202-207.
10. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases. Leuven Lung Cancer Group. Chest. 1997;112:1480-1486.
11. Sasaki M, Ichiya Y, Kuwabara Y, et al. The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography. Eur J Nucl Med. 1996;23:741-747.
12. Steinert HC, Hauser M, Allemann F, et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology. 1997;202:441-446.
13. Higashi K, Ueda Y, Seki H, et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Natl Med. 1998;39:1016-1020.
14. Kim BT, Kim Y. Lee KS, et al. Localized form of bronchioloalveolar carcinoma: FDG PET findings. AJR Am J Roentgenol. 1998;170:935-939.
15. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002;359:1388-1393.
16. Hicks R, Kalff V, MacManus MP, et al. 18F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med. 2001;42:1596-1604.
17. Dwamera BA, Sonnad SS, Angobaldo JO, et al. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s - meta-analytic comparison of PET and CT. Radiology. 1999;213:530-536.
18. Lowe VJ, Naunheim KS: Positron emission tomography in lung cancer. Ann Thorac Surg. 1998;65:1821-1829.
19. Tsubamoto M, Kuriyama K, Kido S, et al. Detection of lung cancer on chest radiographs: analysis on the basis of size and extent of ground-glass opacity at thin-section CT. Radiology. 2002;224:139-144.
20. Roberts PF, Follette DM, von Haag D, et al. Factors associated with false-positive staging of lung cancer by positron emission tomography. Ann Thorac Surg. 2000;70:1154-1159.
21. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500-2507.
22. Cerfolio RJ, Bryant AS, Winokur TS, et al. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg. 2004;78:1903-1909.
23. Ichiya Y, Kuwabara Y, Sasaki M, et al. A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma. Ann Nucl Med. 1996;10:193-200.
24. Bury T, Corhay JL, Duysinx B, et al. Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer. Eur Respir J. 1999;14:1376-1380.